['metastatic colorectal cancer']
['brontictuzumab', 'trifluridine/tipiracil']

        Inclusion Criteria:

          -  Histologically confirmed metastatic colorectal cancer (mCRC) previously treated with
             fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF
             biological therapy, and if KRAS wild-type, an anti-EGFR therapy

          -  ECOG performance status 0 or 1

        Exclusion Criteria:

          -  Prior treatment with gamma secretase inhibitors or other Notch 1 inhibitors

          -  Subjects with known active HIV infection. Subjects with HIV that are under a stable
             anti-retroviral regimen and have no evidence of immune deficiency (normal CD4 counts),
             undetectable viral load, and no HIV-related infections are eligible

          -  Subjects with uncontrolled diarrhea <30 days prior to first administration of study
             drug

          -  Subjects with any history of or current clinically significant gastrointestinal
             disease including, but not limited to:

               -  Inflammatory bowel disease (including ulcerative colitis and Crohn's disease)

               -  Active peptic ulcer disease

               -  Known intraluminal metastatic lesion(s) with risk of bleeding
      